News
Displaying 181–190 of 519
-
ProQR Doses First Patients in Phase 2/3 Clinical Trials for its USH2A-Exon 13 RNA Therapy
Research NewsThe Sirius trial is for USH2A (exon 13 mutations) patients with advanced vision loss. The Celeste trial is for USH2A (exon 13 mutations) patients with moderate to early vision loss.
-
Foundation News
Program to have special translational research emphasis on inherited macular dystrophy.
-
Eyes On Eyecare Raises $1,500 for Foundation Fighting Blindness
In the PressOver 1,400 people participated in charitable giving initiative.
-
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
Research NewsThe clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
Foundation News
This December 16th exclusive in-person performance and conversation with the Blind Boys of Alabama will raise awareness for blinding diseases.
-
In the Press
Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and Florence Paliargues appointed as VP Portfolio Project Management.
-
RD Fund Announces Fundraising Efforts Underway for RD Fund 2
Foundation NewsPatient-centric venture philanthropy model continues to invest in companies developing therapies for individuals affected by retinal degenerative diseases.
-
FDA Approves Genentech’s Susvimo for Treating Wet AMD
Research NewsThe approach significantly reduces the need for regular ocular injections.
-
Opus Genetics Announces Two Key Leadership Appointments
In the PressDr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
-
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
Research NewsThe emerging gene therapy is being designed to more safely reach the fovea
.png)
.png)
